New antibody cocktail shows promise in lung cancer trial
NCT ID NCT07330596
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether adding a new drug called QL1706 (which targets two immune checkpoints) to standard chemotherapy can help people with advanced non-small cell lung cancer whose disease has progressed after initial immunotherapy. About 96 participants will receive either the combination or chemotherapy alone. The goal is to see if the combination delays cancer growth and improves response rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QL1706 (a combination of two antibodies targeting PD-1 and CTLA-4) plus chemotherapy (gemcitabine or docetaxel)
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced lung cancer whose disease has worsened after initial immunotherapy.
- What could go wrong
- This is a small, early-phase (Phase 2) study with only 96 participants, so results may not apply to everyone. The combination may cause significant side effects, and it is not yet known if it works better than chemotherapy alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anhui cancer hospital
RECRUITINGHefei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo outsmart tough lung cancer?
- Can a new Antibody-Drug conjugate outsmart advanced lung cancer?
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Drug duo aims to tackle tough lung cancers after first treatment fails
- Blood test may let cancer patients take safe breaks from immunotherapy
- New combo aims to stall lung cancer when targeted pills start to fail